Loading...
•
Mar 31, 2020
Enanta Pharmaceuticals Q2 2020 Earnings Report
Enanta Pharmaceuticals reported financial results for the fiscal second quarter ended March 31, 2020.
Key Takeaways
Enanta Pharmaceuticals reported a total revenue of $27.6 million for the three months ended March 31, 2020, primarily from royalty revenue. The company's net loss for the quarter was $6.0 million, or a loss of $0.30 per diluted common share. Cash and marketable securities totaled $435.4 million at March 31, 2020.
On track to initiate Phase 1b study of EDP-514 in Viremic Hepatitis B Patients in 2Q 2020 and Phase 1 Study of EDP-297 in 3Q 2020
Royalty Revenue for the Quarter was $27.6 Million
Cash and Marketable Securities Totaled $435.4 Million at March 31, 2020
The company plans to initiate Phase 2 dose ranging study in pediatric patients with RSV in 4Q 2020, and a Phase 2 study in adult transplant patients with RSV in 4Q 2020
Enanta Pharmaceuticals
Enanta Pharmaceuticals
Enanta Pharmaceuticals Revenue by Segment
Revenue by Segment
Royalty Revenue
CapyFin.com Forward Guidance
Enanta expects that its current cash, cash equivalents and marketable securities, as well as its continuing royalty revenue, will be sufficient to meet the anticipated cash requirements of its existing business and development programs for the foreseeable future.